Newsletters and Deep Dive digital magazine
I recently had the pleasure of attending the PING Conference 2022, which had the tagline of ‘
In the fourth in her series of five articles looking at the objectives of the PPRS, Leela Barham focuses on whether the Pharmaceutical Price Regulation Scheme (PPRS) has delivered on the aim of
The Association of the British Pharmaceutical Industry (ABPI) has been refused a legal challenge to a cap on the cost of new drugs. It has accepted defeat - but it will leave a bitter taste fo
In the third in her series of five articles, Leela Barham considers the extent to which the third of the UK PPRS’ objectives – to keep the branded medicines bill within affordable limits – has
Proposals have been made to reduce NHS spending on 'low-value' prescriptions to redirect the savings to fund new drugs.
If we learned anything at CAR-TCR it’s that CAR-T therapies are still a relatively new treatment modality and innovation is happening along many different axes.
Drug discovery is usually a goal-driven and iterative process, as researchers look for innovative new routes to target particular diseases and study those diseases in afflicted patients to learn ho